Wence Shi1,2, Lu Yan1,2, Jingang Yang1,2, Mengyue Yu1,2. 1. State Key Laboratory of Cardiovascular Disease. 2. Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
BACKGROUND: Pharmacokinetic and pharmacodynamic study showed a lower clopidogrel response when coprescribed with proton pump inhibitors (PPIs). Despite this, PPIs is necessary for patients treated with long term dual antiplatelet therapy (DAPT). Ethnic variance also played a different effect on clopidogrel response. Our study evaluated the effect of concomitant use of DAPT and PPIs and assessed whether ethnic variance exert different effect on clinical outcomes. METHODS: We carefully searched EMBASE, PubMed/Medline databases, and the Cochrane library in April 2019. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) and individual endpoints reported. We also focused on bleeding events. Studies were excluded if the follow-up were <12 months and patients were not treated with clopidogrel after stent implantation. RESULTS: A total of 18 studies were included in the systematic review (involving 79,670 patients). No randomized controlled trials (RCTs) were included. PPIs comedication were associated with increased MACCE (odds ratio [OR] = 1.38; 95% confidence interval [CI] = 1.28-1.49) while not associated with decreased bleeding risks, such as gastrointestinal bleeding (OR = 1.05; 95% CI = 0.53-2.11). PPIs comedication were associated with increased risk for all endpoints among Caucasian population while not with increased risk for MACE (OR = 1.20; 95% CI = 0.99-1.39), all-cause death (OR = 1.24; 95% CI = 0.74-2.06), cardiac-death (OR = 1.29; 95% CI = 0.64-2.57) among Asian population. CONCLUSION: PPIs comedication were associated with adverse clinical outcomes, and ethnic variance may exert different effect on clinical outcomes. Subgroup analysis indicated that concomitant use of PPI might be suitable for Asian patients after stent implantation.
BACKGROUND: Pharmacokinetic and pharmacodynamic study showed a lower clopidogrel response when coprescribed with proton pump inhibitors (PPIs). Despite this, PPIs is necessary for patients treated with long term dual antiplatelet therapy (DAPT). Ethnic variance also played a different effect on clopidogrel response. Our study evaluated the effect of concomitant use of DAPT and PPIs and assessed whether ethnic variance exert different effect on clinical outcomes. METHODS: We carefully searched EMBASE, PubMed/Medline databases, and the Cochrane library in April 2019. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) and individual endpoints reported. We also focused on bleeding events. Studies were excluded if the follow-up were <12 months and patients were not treated with clopidogrel after stent implantation. RESULTS: A total of 18 studies were included in the systematic review (involving 79,670 patients). No randomized controlled trials (RCTs) were included. PPIs comedication were associated with increased MACCE (odds ratio [OR] = 1.38; 95% confidence interval [CI] = 1.28-1.49) while not associated with decreased bleeding risks, such as gastrointestinal bleeding (OR = 1.05; 95% CI = 0.53-2.11). PPIs comedication were associated with increased risk for all endpoints among Caucasian population while not with increased risk for MACE (OR = 1.20; 95% CI = 0.99-1.39), all-cause death (OR = 1.24; 95% CI = 0.74-2.06), cardiac-death (OR = 1.29; 95% CI = 0.64-2.57) among Asian population. CONCLUSION: PPIs comedication were associated with adverse clinical outcomes, and ethnic variance may exert different effect on clinical outcomes. Subgroup analysis indicated that concomitant use of PPI might be suitable for Asian patients after stent implantation.
Authors: Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon Journal: N Engl J Med Date: 2010-10-06 Impact factor: 91.245
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: Circulation Date: 2016-03-29 Impact factor: 29.690
Authors: Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine Journal: Eur Heart J Date: 2018-01-14 Impact factor: 29.983
Authors: Dirk Sibbing; Tanja Morath; Julia Stegherr; Siegmund Braun; Wolfgang Vogt; Martin Hadamitzky; Albert Schömig; Adnan Kastrati; Nicolas von Beckerath Journal: Thromb Haemost Date: 2009-04 Impact factor: 5.249
Authors: Giora Weisz; Nathaniel R Smilowitz; Ajay J Kirtane; Michael J Rinaldi; Rupa Parvataneni; Ke Xu; Thomas D Stuckey; Akiko Maehara; Bernhard Witzenbichler; Franz-Josef Neumann; D Christopher Metzger; Timothy D Henry; David A Cox; Peter L Duffy; Bruce R Brodie; Ernest L Mazzaferri; Roxana Mehran; Gregg W Stone Journal: Circ Cardiovasc Interv Date: 2015-10 Impact factor: 6.546
Authors: Antonis A Manolis; Theodora A Manolis; Helen Melita; Niki Katsiki; Antonis S Manolis Journal: Eur J Intern Med Date: 2019-11-30 Impact factor: 4.487
Authors: Berit E S Jensen; Jane M Hansen; Kasper S Larsen; Anders B Junker; Jens F Lassen; Svend E Jensen; Ove B Schaffalitzky de Muckadell Journal: Eur J Gastroenterol Hepatol Date: 2017-10 Impact factor: 2.566